Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.40 - $25.88
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.72M
Market Cap
$4.14B
Enterprise Value$2.93B
Total Cash (Recent Filing)$762.00M
Total Debt (Recent Filing)$44.60M
Price to Earnings (P/E)18.4
Beta1.12
Next Earnings
Nov 11, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding168,712,220
10 Day Avg. Volume1,946,690
30 Day Avg. Volume1,715,543
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda27.59
Forecast
1Y Price Target
$29.75Price Target Upside21.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Product AdoptionDiscontinuations remain below 10%, which is very good news for continued growth for this franchise.
Sales GrowthDaybue generated $96.1M in sales, marking 14% year-over-year growth with steady increases in patient uptake and persistency.
Bears Say
Patient Adoption ChallengesThe adoption might be highest among newly diagnosed patients as existing patients and caregiver networks are often educated on risk benefit profile of Daybue from the foundation network or Facebook patient groups which might have adverse effect on the adoption for a proportion of existing patients.
Risk AssessmentThere is some risk associated with the upcoming Phase 3 data for ACP-101 in Prader-Willi syndrome, which could affect investor perception.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $25.88 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $4.14B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.022.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 168,712,220 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.16 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.75 (21.28% Upside)
$29.75 (21.28% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 306.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $314.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
33.18%
Trailing 12-Months
Asset Growth
34.07%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted ACADIA's strong revenue growth driven by DAYBUE and NUPLAZID sales, successful direct-to-consumer campaigns, and a robust pipeline expansion. However, there were concerns about increased SG&A expenses and inherent risks in pipeline development. Overall, the positive aspects of revenue growth and strategic initiatives outweigh the lowlights.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$29.75
▲(21.28% Upside)
Technical Analysis
ImmunityBio
―
Merus
―
Apellis Pharmaceuticals
―
Immunovant
―
MoonLake Immunotherapeutics
―
Ownership Overview
23.95% Insiders
16.32% Mutual Funds
1.11% Other Institutional Investors
34.66% Public Companies and
Individual Investors